Vertex and Republic of Ireland Reach Agreement on Reimbursement for Triple Combination Therapy
Patients with cystic fibrosis (CF) in the Republic of Ireland will be among the first in Europe to benefit from Vertex Pharmaceuticals’...
5 New Drug Approvals the FDA Gave Top Priority
The U.S. Food and Drug Administration's made it clear that granting a priority review to an application isn't exactly the same thing as...
Long-awaited cystic fibrosis drug could turn deadly disease into a manageable condition
A new cystic fibrosis therapy dramatically improved patients’ lung function and showed clear signs of targeting the genetic root of the...
New Vertex cystic fibrosis drug approved, extending treatments to 90% of patients
Vertex Pharmaceuticals on Monday won approval for its fourth treatment for cystic fibrosis, a combination drug that extends a new form of...
5,000 Expected to Attend Cystic Fibrosis Conference, NACFC 2019, in Nashville
The Western Hemisphere’s largest gathering of experts in cystic fibrosis gets underway later this month in Nashville, Tennessee — site of...
Kalydeco’s Efficacy Tied to Phosphorylation Levels of CFTR Protein, Study Suggests
CFTR channel activity is controlled by a molecular process known as phosphorylation. Now, a study suggests that the levels of...
FDA to Review Elexacaftor, Tezacaftor, Ivacaftor Combo for Cystic Fibrosis
The Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for elexacaftor (VX-445),...
Kalydeco’s Safety and Benefits Studied in CF Patients with Severe Lung Disease
Treatment with Kalydeco (ivacaftor) improved lung function, exercise capacity, and sweat chloride concentration in cystic fibrosis (CF)...
FDA Approves Kalydeco for Treatment of 6- to 12-month-old Infants with Cystic Fibrosis
The U.S. Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) for the treatment of infants from six to 12 months old, who...
Vertex Pharma (VRTX) Receives Approval for SYMDEKO in Australia to Treat Underlying Cause of CF
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Therapeutic Goods Administration (TGA) of Australia has...
